Skip to content
OpenCapital
Get started

BioRestorative Therapies BRTX Q4 2024 Annual earnings

Reported March 27, 2025 · After market close

Revenue$43.3KMiss by $431.7K
EPS-$0.20Beat by $0.07
Revenue estimate$475.0K
EPS estimate-$0.27

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$600.0K
EPS estimate-$0.15

Versus estimates

Revenue

Q1 2026$23.2KMiss by $289.3KQ4 2025$20.0KMiss by $130.0KQ3 2025$11.8KMiss by $448.2KQ2 2025$303.3KBeat by $103.3KQ1 2025$25.0KMiss by $355.0K
Q4 2024$43.3KMiss by $431.7K

Diluted EPS

Q1 2026-$0.19Beat by $0.01Q4 2025-$0.37In lineQ3 2025-$0.33Beat by $0.03Q2 2025-$0.30Beat by $0.11Q1 2025-$0.56Miss by $0.24
Q4 2024-$0.20Beat by $0.07

Ask the moment BioRestorative Therapies reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did BioRestorative Therapies report Q4 2024 earnings?
BioRestorative Therapies (BRTX) reported Q4 2024 earnings on March 27, 2025 after market close.
What were BioRestorative Therapies's Q4 2024 revenue and EPS?
BioRestorative Therapies reported revenue of $43.3K and eps of $-0.20 for Q4 2024.
Did BioRestorative Therapies beat estimates in Q4 2024?
Revenue missed the consensus estimate of $475.0K by $431.7K. EPS beat the consensus estimate of $-0.27 by $0.07.
Where can I find BioRestorative Therapies's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001641172-25-001011) directly on SEC EDGAR. The filing index links above go to sec.gov.